EXACT Therapeutics announces grant of core patent in the U.S.
EXACT Therapeutics announces grant of core patent in the U.S.
Oslo, Norway, 8 July, 2025 - EXACT Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology, has been informed that the United States Patent and Trademark Office (USPTO) has granted EXACT its U.S. Patent No. 12,343,396 entitled “Ultrasound mediated delivery of drugs”.
The granted patent covers the treatment of patients with a pharmaceutical using EXACT’s proprietary agent PS101 and Acoustic Cluster Therapy (ACT®).
Per Walday, CEO of EXACT Therapeutics, comments, ”We are very pleased to announce the granting of this all important core patent for PS101 and the ACT technology in the U.S., the world’s largest pharmaceutical market. Our U.S. development of ACT is progressing as planned, marked by the dosing of the first patient in the Phase 2 ENACT trial in locally advanced pancreatic cancer at a U.S. hospital, as reported on 24 June.”
About Exact Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT has an on-going Phase 2 trial for the treatment of locally advanced pancreatic cancer. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX).
www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: [email protected]